Skip to content
Disclosery

Octagon Capital Advisors LP

Follow

13F filer, CIK 1839435, NEW YORK, NY

Octagon Capital Advisors LP reported $455,625,029 across 30 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14. Its ten largest share positions make up 60.57% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001839435-25-000007

Period
2025-06-30
Reported value
$456M
Holdings
30
Top 10 weight
60.57%
New
3
Sold out
8

Largest buys vs the previous quarter

SecurityShares changeApprox. value
SPRYadded+725,000$12.7M
KYMRnew+266,000$11.6M
VERONA PHARMA PLCadded+119,736$11.3M
DBVTnew+1,018,021$9.31M
UNCYnew+1,000,000$4.77M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
NUVATION BIO INCreduced-27,176,688-$53M
APLSreduced-1,190,500-$20.6M
SNDXexited-904,000-$11.1M
SRRKexited-329,000-$10.6M
VSTMexited-1,720,000-$10.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001839435-25-000007, largest first. % of portfolio is the value over $455,625,029, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,746,667 shares; 2024Q4: 2,110,167 shares; 2025Q1: 2,341,667 shares; 2025Q2: 2,341,667 shares 2,341,667$43.6M9.57%0Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,976,387 shares; 2024Q4: 2,059,387 shares; 2025Q1: 2,059,387 shares; 2025Q2: 1,946,054 shares 1,946,054$42.4M9.3%-113,333Timeline
VERONA PHARMA PLCVERONA PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,835,200 shares; 2024Q4: 571,264 shares; 2025Q1: 217,264 shares; 2025Q2: 337,000 shares 337,000$31.9M7%+119,736
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,572,222 shares; 2024Q4: 10,450,000 shares; 2025Q1: 10,700,000 shares; 2025Q2: 12,592,500 shares 12,592,500$29.1M6.38%+1,892,500Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 625,000 shares; 2025Q2: 1,350,000 shares 1,350,000$23.6M5.17%+725,000Timeline
GOSSGOSSAMER BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 9,187,883 shares; 2024Q4: 18,350,000 shares; 2025Q1: 18,350,000 shares; 2025Q2: 18,350,000 shares 18,350,000$22.6M4.95%0Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,425,000 shares; 2024Q4: 2,425,000 shares; 2025Q1: 2,425,000 shares; 2025Q2: 2,425,000 shares 2,425,000$22.5M4.94%0Timeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 308,000 shares; 2025Q1: 308,000 shares; 2025Q2: 389,000 shares 389,000$20.5M4.49%+81,000
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 3,322,000 shares; 2025Q2: 3,672,000 shares 3,672,000$20.1M4.41%+350,000Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,305,000 shares; 2024Q4: 2,763,000 shares; 2025Q1: 2,763,000 shares; 2025Q2: 2,763,000 shares 2,763,000$19.8M4.35%0Timeline
ATYRATYR PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 900,000 shares; 2025Q1: 3,552,000 shares; 2025Q2: 3,820,000 shares 3,820,000$19.4M4.25%+268,000Timeline
APLSAPELLIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,006,980 shares; 2024Q4: 3,006,980 shares; 2025Q1: 2,094,000 shares; 2025Q2: 903,500 shares 903,500$15.6M3.43%-1,190,500Timeline
NUVBNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 12,171,513 shares; 2024Q4: 9,202,907 shares; 2025Q1: 7,900,000 shares; 2025Q2: 7,691,334 shares 7,691,334$15M3.29%-208,666Timeline
Tourmaline Bio IncTourmaline Bio IncQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 905,000 shares; 2025Q2: 905,000 shares 905,000$14.5M3.18%0
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 1,370,000 shares; 2025Q1: 1,370,000 shares; 2025Q2: 1,273,333 shares 1,273,333$14.4M3.16%-96,667Timeline
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,018,000 shares; 2024Q4: 3,018,000 shares; 2025Q1: 3,018,000 shares; 2025Q2: 2,130,000 shares 2,130,000$13.8M3.03%-888,000
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,012,052 shares; 2024Q4: 1,993,052 shares; 2025Q1: 1,425,000 shares; 2025Q2: 1,030,000 shares 1,030,000$13.5M2.97%-395,000Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 620,470 shares; 2024Q4: 778,000 shares; 2025Q1: 769,815 shares; 2025Q2: 672,595 shares 672,595$11.8M2.6%-97,220Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 266,000 shares 266,000$11.6M2.55%newTimeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,230,000 shares; 2025Q2: 1,267,000 shares 1,267,000$9.69M2.13%+37,000Timeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,018,021 shares 1,018,021$9.31M2.04%newTimeline
CRBPCORBUS PHARMACEUTICALS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,115,000 shares; 2024Q4: 1,115,000 shares; 2025Q1: 1,115,000 shares; 2025Q2: 1,115,000 shares 1,115,000$7.69M1.69%0Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 296,000 shares; 2025Q2: 148,000 shares 148,000$6.99M1.53%-148,000Timeline
UNCYUNICYCIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,000,000 shares 1,000,000$4.77M1.05%newTimeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 15,000 shares; 2024Q4: 303,000 shares; 2025Q1: 303,000 shares; 2025Q2: 303,000 shares 303,000$4.53M0.99%0Timeline
HELIX ACQUISITION CORP IIHELIX ACQUISITION CORP IIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 250,000 shares; 2024Q4: 250,000 shares; 2025Q1: 250,000 shares; 2025Q2: 250,000 shares 250,000$2.66M0.58%0
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 468,000 shares; 2025Q2: 177,667 shares 177,667$2.18M0.48%-290,333Timeline
KLRSKALARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 481,000 shares; 2025Q2: 360,000 shares 360,000$961K0.21%-121,000Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 5,136,795 shares; 2025Q1: 5,136,795 shares; 2025Q2: 700,000 shares 700,000$889K0.2%-4,436,795Timeline
NUVATION BIO INCNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 312,336 shares; 2024Q4: 312,336 shares; 2025Q1: 27,330,800 shares; 2025Q2: 154,112 shares 154,112$301K0.07%-27,176,688

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SNDXSYNDAX PHARMACEUTICALS INC904,000$11.1Mshares
SRRKSCHOLAR ROCK HLDG CORP329,000$10.6Mshares
VSTMVERASTEM INC1,720,000$10.4Mshares
CNTACENTESSA PHARMACEUTICALS PLC600,000$8.63Mput
REGULUS THERAPEUTICS INCREGULUS THERAPEUTICS INC4,637,076$8.11Mshares
VRDNVIRIDIAN THERAPEUTICS INC450,000$6.07Mshares
UNICYCIVE THERAPEUTICS INCUNICYCIVE THERAPEUTICS INC10,000,000$5.75Mshares
CATXPERSPECTIVE THERAPEUTICS INC2,250,000$4.79Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001839435-25-000007 base2025-08-14acceptance time not in the bulk data set